Clinical Trial Update: A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing NN5401 with biphasic insulin aspart 30 in type 2 diabetes completed with posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)
• NN5401

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-11-20